Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
27 results
  • Pancreatic Cancer, Lung Cancer, Colorectal Cancer

25-110          Phase I

3263-001: A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations

  • Colorectal Cancer

24-643          Phase II

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

  • Pancreatic Cancer, Sarcoma, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Colorectal Cancer, Bladder Cancer

25-464          Phase I

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 in Participants with Advanced Solid Tumors

  • Prostate Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Bladder Cancer

23-452          Phase I

A Phase 1, First-in-Human, Dose Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

  • Pancreatic Cancer, Colorectal Cancer, Lung Cancer

25-022          Phase I

A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants with KRAS G12D Mutated Advanced Solid Tumors

  • Prostate Cancer, Pancreatic Cancer, Melanoma, Lung Cancer, Head and Neck Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Ovarian Cancer

25-287          Phase I

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

  • Pancreatic Cancer, Lung Cancer, Colorectal Cancer

25-375          Phase I

A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS PI3Ka inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors

  • Gastric (Stomach) Cancer, Lung Cancer, Colorectal Cancer

23-340          Phase II

A Phase 1/2 Study of FOG-001 in Participants with Locally Advanced or Metastatic Solid Tumors

  • Lung Cancer, Kidney Cancer, Head and Neck Cancer, Gastric (Stomach) Cancer, Bladder Cancer, Pancreatic Cancer, Esophageal Cancer, Cervical Cancer, Colorectal Cancer

25-448          Phase II

A Phase 1/2 Study of GEN1286 in Patients with Advanced Solid Tumors

  • Melanoma, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Breast Cancer

22-577          Phase II

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)

Showing 1 - 10 of 27 results